Optibrium and Collaborative Drug Discovery partner on integration of StarDrop with CDD Vault
Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery.
Optibrium and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, are collaborating to integrate the StarDrop and CDD Vault platforms. This creates a seamless connection in real time between project data, securely held and managed in CDD Vault, and StarDrop’s unique compound design and optimisation capabilities. Instant access to the latest assay and compound data, with which a project team can share, interpret and model their chemistry, will lead to better decisions and shorter project timelines.
CDD Vault is a hosted biological and chemical database that securely manages project data. It allows researchers, across academic laboratories, research foundations, as well as small and large companies, to intuitively organise chemical structures and biological study data. CDD Vault supports a unique collaborative model that enables data to be safely shared with internal or external partners through an easy-to-use web interface.
Researchers can now seamlessly retrieve their biological results from CDD Vault using an intuitive search interface within StarDrop that enables users to easily run CDD Vault queries, returning the results directly in StarDrop. This extension to StarDrop is available free of charge to existing StarDrop and CDD Vault users, providing a highly visual way to interpret these data and their relationships with compound structures, clearly highlighting the best chemistries and multi-parameter optimisation strategies for drug discovery.
Dr Matthew Segall, CEO of Optibrium, commented: “When selecting compounds the importance of working with the most up-to-date data can’t be over stated – incomplete or out-of-date information results in time and effort being wasted. With this in mind, our aim is for StarDrop to fully integrate with the very ‘best in class’ drug discovery informatics platforms and we are delighted to be working with CDD to support drug discovery project teams to make good decisions and achieve their optimisation goals faster.”
Dr Barry Bunin, CEO CDD, added: “CDD understands that efficiency in modern drug discovery is a function of how well the industry's thought leaders work together. To that end, we are delighted to collaborate with Optibrium through this integration between StarDrop and CDD Vault. CDD Vault is particularly strong for project teams working across disciplines and, when coupled with StarDrop's unique ability to help scientists make confident and objective decisions, will undoubtedly help drug discovery project teams manage, analyze, and present chemical structures and biological assay data."
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance